πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

205 results for β€œgroup” Clear

  1. Treatment group

    United Therapeutics Europe Ltd

    Post Operative Surgical Site Infection

    phase 3 small molecule completed

    1 trial

  2. batch 1 of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) (MCV4)

    CanSino Biologics

    Meningococcal Meningitis

    phase 3 mab active

    1 trial

  3. 0.2mg group

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Opioid Dependence

    phase 2 small molecule active

    1 trial

  4. 3D hypoxia-preconditioned UC-MSC group

    The First People's Hospital of Lianyungang

    Severe Aplastic Anemia (SAA)

    phase 2 small molecule active

    1 trial

  5. A parallel-group treatment, Phase 2a, multicenter, randomized, double-blind, placebo-controlled umbrella study to evaluate the efficacy and safety of frexalimab, brivekimig and rilzabrutinib in participants aged 16 to 75 years with primary focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD)

    Sanofi-aventis Healthcare Pty Ltd

    Immune system diseases

    phase 2 other active

    1 trial

  6. A phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety, tolerability, and efficacy of S-337395 in symptomatic nonhospitalized adults with respiratory syncytial virus who are at high risk of progression to severe disease

    Shionogi B.V.

    Respiratory Syncytial Virus

    phase 2 other active

    1 trial

  7. A study in two groups of healthy male adult participants to assess how much test medicine (SAR441566) is taken up, degraded and removed by the body and to assess the extent to which SAR441566 becomes available to the body when given by mouth

    Sanofi-aventis Healthcare Pty Ltd

    Healthy volunteers

    phase 2 other active

    1 trial

  8. ATA188

    Evidence Based Cataract Study Group

    Primary Progressive Multiple Sclerosis

    phase 2 mab terminated

    1 trial

  9. Active treatment with a high dose of BGS649

    Mereo BioPharma Group plc

    Endometriosis

    phase 2 small molecule completed

    1 trial

  10. Alvelestat

    Mereo BioPharma Group plc

    Covid19

    phase 2 small molecule completed

    1 trial

  11. Alvelestat (MPH966)

    Mereo BioPharma Group plc

    Alpha-1 Antitrypsin Deficiency (AATD)

    phase 2 small molecule completed

    1 trial

  12. Ara-C Group

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  13. Arm 1： Standard Synchronous Group

    The First People's Hospital of Lianyungang

    Advanced Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  14. BCT197

    Mereo BioPharma Group plc

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule completed

    1 trial

  15. BCT197

    Mereo BioPharma Group plc

    Pulmonary Disease, Chronic Obstructive

    phase 2 small molecule completed

    1 trial

  16. BCT197 Part A

    Mereo BioPharma Group plc

    Acute Kidney Injury

    phase 2 small molecule terminated

    1 trial

  17. BGS649

    Mereo BioPharma Group plc

    Hypogonadotropic Hypogonadism

    phase 2 small molecule completed

    2 trials

  18. BGS649

    Mereo BioPharma Group plc

    Pelvic Pain Associated With Refractory Endometriosis

    phase 2 small molecule terminated

    1 trial

  19. BPS804

    Mereo BioPharma Group plc

    Chronic-kidney Disease Stage 5D on Stable Hemodialysis

    phase 2 small molecule terminated

    1 trial

  20. BPS804

    Mereo BioPharma Group plc

    Osteogenesis Imperfecta

    phase 2 small molecule terminated

    1 trial

  21. BPS804

    Mereo BioPharma Group plc

    Hypophosphatasia

    phase 2 small molecule completed

    1 trial

  22. BPS804 20mg/Kg

    Mereo BioPharma Group plc

    Osteopenia

    phase 2 small molecule completed

    1 trial

  23. C4531029:A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Dose-Ranging Study to Investigate the Efficacy and Safety of PF-07275315 in Adult Participants with Inadequately Controlled Moderate-to-Severe Asthma

    Pfizer Australia Pty Ltd

    Moderate-to-severe Asthma

    phase 2 other active

    1 trial

  24. CMV-pp65 CTLs

    Evidence Based Cataract Study Group

    Cytomegalovirus

    phase 2 mab completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources